Table 3.
Shifts in BMD T-scores# (baseline to Week 52; BMD population)
| Baseline T-score | Post-baseline T-score | |||
|---|---|---|---|---|
| ≤−2.5 | >−2.5 and ≤−1 | >−1 | ||
| Osteoporotic | Osteopenic | Normal | ||
| Shifts in T-scores for lumbar spine BMD (L2–L4) | ||||
| BGF MDI 320/18/9.6 μg (N = 128)¶ | ≤−2.5 (n = 0) | 0 | 0 | 0 |
| >−2.5 and ≤ −1 (n = 37) | 0 | 35 (94.6) | 2 (5.4) | |
| >−1 (n = 91) | 0 | 4 (4.4) | 87 (95.6) | |
| BFF MDI 320/9.6 μg (N = 57)¶ | ≤−2.5 (n = 0) | 0 | 0 | 0 |
| >−2.5 and ≤−1 (n = 16) | 0 | 14 (87.5) | 2 (12.5) | |
| >−1 (n = 41) | 0 | 3 (7.3) | 38 (92.7) | |
| GFF MDI 18/9.6 μg (N = 123)¶ | ≤−2.5 (n = 0) | 0 | 0 | 0 |
| >−2.5 and ≤−1 (n = 35) | 0 | 26 (74.3) | 9 (25.7) | |
| >−1 (n = 88) | 0 | 4 (4.5) | 84 (95.5) | |
| Shifts in T-scores for total hip BMD | ||||
| BGF MDI 320/18/9.6 μg (N = 128)¶ | ≤−2.5 (n = 0) | 0 | 0 | 0 |
| >−2.5 and ≤−1 (n = 52) | 3 (5.8) | 45 (86.5) | 4 (7.7) | |
| >−1 (n = 76) | 0 | 5 (6.6) | 71 (93.4) | |
| BFF MDI 320/9.6 μg (N = 57)¶ | ≤−2.5 (n = 0) | 0 | 0 | 0 |
| >−2.5 and ≤−1 (n = 18) | 1 (5.6) | 16 (88.9) | 1 (5.6) | |
| >− 1 (n = 39) | 0 | 5 (12.8) | 34 (87.2) | |
| GFF MDI 18/9.6 μg (N = 119)¶ | ≤−2.5 (n = 0) | 0 | 0 | 0 |
| >−2.5 and ≤−1 (n = 52) | 1 (1.9) | 50 (96.2) | 1 (1.9) | |
| >−1 (n = 67) | 0 | 4 (6.0) | 63 (94.0) | |
Data are n (%). BMD Bone mineral density, BFF Budesonide/formoterol fumarate, BGF Budesonide/glycopyrrolate/formoterol fumarate, GFF Glycopyrrolate/formoterol fumarate, L Lumbar spine segment, MDI Metered dose inhaler. #: shifts are from baseline to the worst post-baseline value, ¶: N = number of patients with available data for both baseline and post-baseline T-scores (non-missing)